Page 851 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPtEr 59 Large-Vessel Vasculitides 823

Calcium and vitamin D supplementation should be part of the Please check your eBook at https://expertconsult.inkling.com/
therapeutic regimen. for self-assessment questions. See inside cover for registration
In many, but not all, patients, immunosuppressive treatment details.
can be discontinued 18–24 months after diagnosis. Markers of
systemic inflammation may remain elevated, and continuous REFERENCES
monitoring for aortic involvement and recurrence of cranial
arteritis is recommended. 1. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J
Med 2003;349(2):160–9.
Most patients with PMR are sufficiently treated with an initial 2. Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and
dose of 20 mg of prednisone per day. In some patients, 10 mg giant-cell arteritis. N Engl J Med 2002;347(4):261–71.
of prednisone can induce and sustain a clinical response. Steroids 3. Nordborg E, Nordborg C. Giant cell arteritis: epidemiological clues to its
should be titrated to minimally needed doses to avoid side effects; pathogenesis and an update on its treatment. Rheumatology (Oxford)
tapering usually needs to be slow, over many months. In TA, 2003;42(3):413–21.
long-term management should be tailored to individual patient 4. Vanoli M, Bacchiani G, Origg L, et al. Takayasu’s arteritis: a changing
44
conditions. It has been argued that patients should be maintained disease. J Nephrol 2001;14(6):497–505.
on a low dose of corticosteroids, such as 5–7 mg prednisone 5. Isobe M. Takayasu arteritis revisited: current diagnosis and treatment. Int
daily, even after successful control of active disease. J Cardiol 2013;168(1):3–10.
Given the age at disease onset in TA, preventive measures to 6. Numano F, Kishi Y, Tanaka A, et al. Inflammation and atherosclerosis.
counteract accelerated atherosclerosis and optimize blood pressure Atherosclerotic lesions in Takayasu arteritis. Ann N Y Acad Sci
2000;902:65–76.
control are important aspects of management. 7. Wagner AD, Goronzy JJ, Weyand CM. Functional profile of tissue-
It has been suggested that up to 50% of patients with TA may infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for
44
require a second immunosuppressive agent. Steroid-sparing two components of the disease. J Clin Invest 1994;94(3):1134–40.
effects of methotrexate have been reported for some patients. 8. Baldini M, Maugeri N, Ramirez GA, et al. Selective up-regulation of the
Similarly, mycophenolate mofetil may have clinical efficiency, soluble pattern-recognition receptor pentraxin 3 and of vascular
although only published data on a small patient cohort are endothelial growth factor in giant cell arteritis: relevance for recent optic
available. Empirically, azathioprine may have a place in main- nerve ischemia. Arthritis Rheum 2012;64(3):854–65.
tenance therapy of patients with TA. Finally, there may be a place 9. Nadkarni S, Dalli J, Hollywood J, et al. Investigational analysis reveals a
for agents blocking TNF-α in patients with persistent disease potential role for neutrophils in giant-cell arteritis disease progression.
Circ Res 2014;114(2):242–8.
activity. Results from well-designed placebo-controlled treatment 10. Roche NE, Fulbright JW, Wagner AD, et al. Correlation of interleukin-6
trials testing the efficiency of such immunosuppressive drugs production and disease activity in polymyalgia rheumatica and giant cell
are awaited. arteritis. Arthritis Rheum 1993;36(9):1286–94.
Detecting and treating hypertension is an essential component 11. Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell
of caring for patients with TA. Untreated hypertension leads to arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis
acceleration of atherosclerosis and cardiac insufficiency. In patients Rheum 2000;43(5):1041–8.
with upper-extremity involvement, obtaining accurate blood 12. Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell
pressure measurements is a challenge and requires education of arteritis. N Engl J Med 2017;377:317–28.
the patient and caregivers. 13. O’Neill L, Rooney P, Molloy D, et al. Regulation of inflammation and
angiogenesis in giant cell arteritis by acute-phase serum amyloid A.
Revascularization Procedures Arthritis Rheumatol 2015;67(9):2447–56.
14. Weyand CM, Goronzy JJ. Immune mechanisms in medium and
Besides pharmacological therapy, revascularization procedures— large-vessel vasculitis. Nat Rev Rheumatol 2013;9(12):731–40.
including both surgical and endovascular interventions—have 15. Pryshchep O, Ma-Krupa W, Younge BR, et al. Vessel-specific Toll-like
vastly broadened therapeutic options in patients with TA and receptor profiles in human medium and large arteries. Circulation
45
large-vessel GCA. To minimize the risk of complications, such 2008;118(12):1276–84.
as rapid reocclusion, an effort should be made to suppress vascular 16. Ma-Krupa W, Jeon MS, Spoerl S, et al. Activation of arterial wall dendritic
wall inflammation, ideally before subjecting the patients to cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med
revascularization treatment. Conventional bypass grafts are still 2004;199(2):173–83.
considered the method of choice. Percutaneous transluminal 17. Krupa WM, Dewan M, Jeon MS, et al. Trapping of misdirected dendritic
angioplasty can be useful in managing renal artery stenosis or cells in the granulomatous lesions of giant cell arteritis. Am J Pathol
2002;161(5):1815–23.
other short-segment lesions. Bypass surgery is needed in patients 18. Weyand CM, Liao YJ, Goronzy JJ. The immunopathology of giant cell
with cerebrovascular ischemia in whom catastrophic strokes may arteritis: diagnostic and therapeutic implications. J Neuroophthalmol
be prevented by bypassing critical stenosis of cervical vessels 2012;32(3):259–65.
with grafts originating from the aortic arch. Reestablishing flow 19. Weyand CM, Wagner AD, Bjornsson J, et al. Correlation of the
in the upper- and lower-extremity arteries can be complicated topographical arrangement and the functional pattern of
by multiple and long-segment stenosis, and arterial reconstruc- tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest
tions with prosthetic graft materials or veins may be the only 1996;98(7):1642–9.
alternative to obtain long-term patency. Placing of conventional 20. Weyand CM, Schonberger J, Oppitz U, et al. Distinct vascular lesions in
stents can be complicated by eliciting rapid restenosis, and it is giant cell arteritis share identical T cell clonotypes. J Exp Med
not known whether outcomes can be improved by drug-eluting 1994;179(3):951–60.
stents. Occlusive disease of the coronary arteries usually represents 21. Deng J, Younge BR, Olshen RA, et al. Th17 and Th1 T-cell responses in
giant cell arteritis. Circulation 2010;121(7):906–15.
a challenging clinical scenario, and most physicians opt for 22. Watanabe R, Hosgur E, Zhang H, et al. Pro-inflammatory and
conventional bypass surgery. Depending on symptoms, patients anti-inflammatory T cells in giant cell arteritis. Joint Bone Spine 2016;pii:
with aortic regurgitation may require repair of the weakened S1297-319X(16)30124-5. doi:10.1016/j.jbspin.2016.07.005. [Epub ahead
aortic wall. of print].